Prof. Dr. Jens Huober
Chefarzt/Chefärztin
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
Meier W, Burges A, Stähle A, Belau A, Schröder W, Richter B, Wimberger P, Schmalfeldt B, Canzler U, Kreienberg R, Wollschlaeger K, Huober J, Baumann K, Gropp-Meier M, Rau J, du Bois A, Sehouli J. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol 2012; 126:236-40.
04.05.2012Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
04.05.2012Gynecol Oncol 2012; 126:236-40
Meier Werner, Burges Alexander, Stähle Anne, Belau Antje, Schröder Willibald, Richter Barbara, Wimberger Pauline, Schmalfeldt Barbara, Canzler Ulrich, Kreienberg Rolf, Wollschlaeger Kerstin, Huober Jens, Baumann Klaus, Gropp-Meier Martina, Rau Jörn, du Bois Andreas, Sehouli Jalid
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
von Minckwitz G, Mehta K, Nekljudova V, Denkert C, Konecny G, Kaufmann M, Jackisch C, Huober J, Hilfrich J, Eiermann W, Gerber B, Fasching P, Eidtmann H, Costa S, Blohmer J, Untch M, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796-804.
16.04.2012Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
16.04.2012J Clin Oncol 2012; 30:1796-804
von Minckwitz Gunter, Mehta Keyur, Nekljudova Valentina, Denkert Carsten, Konecny Gottfried E, Kaufmann Manfred, Jackisch Christian, Huober Jens, Hilfrich Jörn, Eiermann Wolfgang, Gerber Bernd, Fasching Peter A, Eidtmann Holger, Costa Serban D, Blohmer Jens-Uwe, Untch Michael, Loibl Sibylle
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
Solomayer E, Wallwiener D, Wackwitz B, Krämer B, Huober J, Becker S, Lück H, Janni W, Hirnle P, Gebauer G, Fehm T. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol 2012; 23:2271-2277.
01.03.2012Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients
01.03.2012Ann Oncol 2012; 23:2271-2277
Solomayer E-F, Wallwiener D, Wackwitz B, Krämer B, Huober Jens, Becker S, Lück H-J, Janni W, Hirnle P, Gebauer G, Fehm T
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
26.01.2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
26.01.2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Untch M, Gerber B, Rezai M, Jackisch C, Huober J, Kühn T, Nekljudova V, von Minckwitz G, German Breast Group (GBG), Hanusch C, Tesch H, Kreienberg R, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J, Hilfrich J, Strumberg D, Fasching P, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13:135-44.
17.01.2012Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
17.01.2012Lancet Oncol 2012; 13:135-44
Untch Michael, Gerber Bernd, Rezai Mahdi, Jackisch Christian, Huober Jens, Kühn Thorsten, Nekljudova Valentina, von Minckwitz Gunter, German Breast Group (GBG), Hanusch Claus, Tesch Hans, Kreienberg Rolf, Loibl Sibylle, Bischoff Joachim, Eidtmann Holger, Kaufmann Manfred, Blohmer Jens-Uwe, Hilfrich Jörn, Strumberg Dirk, Fasching Peter A, Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Diagnostic and prognostic use of bone turnover markers
Jörger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res 2012; 192:197-223.
01.01.2012Diagnostic and prognostic use of bone turnover markers
01.01.2012Recent Results Cancer Res 2012; 192:197-223
Jörger Markus, Huober Jens
Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
Huober J, von Minckwitz G. Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?. Breast Care (Basel) 2011; 6:419-426.
15.12.2011Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
15.12.2011Breast Care (Basel) 2011; 6:419-426
Huober Jens, von Minckwitz Gunter
Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
Huober J, Widmer I, von Rohr L, Müller A, von Moos R, Güth U, Aebi S, Rochlitz C, Baumann M, Thürlimann B. Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers. Oncology 2011; 81:160-166.
28.10.2011Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
28.10.2011Oncology 2011; 81:160-166
Huober Jens, Widmer Isabelle, von Rohr Lukas, Müller Andreas, von Moos Roger, Güth Uwe, Aebi Stefan, Rochlitz Christoph, Baumann Michael, Thürlimann Beat
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober J, Thürlimann B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2011
14.10.2011Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
14.10.2011Ann Oncol 2011
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober Jens, Thürlimann Beat, on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
Huober J, Nimmrich I, May C, Beckmann M, Baumgärtner A, Kubista E, Ragosch V, Azim H, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2011; 21:27-33.
08.09.2011Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial
08.09.2011Breast 2011; 21:27-33
Huober Jens, Nimmrich I, May C, Beckmann M W, Baumgärtner A K, Kubista E, Ragosch V, Azim H A, Paepke S, Reimer T, Thomssen C, Wallwiener D, Petruzelka L, Barsoum M, Fasching P A, Harbeck N
Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
Baumann K, Lück H, Vergote I, Schmalfeldt B, Huober J, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32.
05.07.2011Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group
05.07.2011Gynecol Oncol 2011; 123:27-32
Baumann K, Lück H J, Vergote I, Schmalfeldt B, Huober Jens, Sehouli J, Loibl S, du Bois A, Kurzeder C, Burchardi N, Wimberger P, Pfisterer J, Wagner U
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
12.06.2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
12.06.2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Joly F, Huober J, Dell'Anna T, Ferrandina G, Vergote I, Reinthaller A, Vaughan M, Sugimoto A, Boman K, Donoghoe M, Fabbro M, Ray-Coquard I, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 2011; 122:226-32.
14.05.2011Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
14.05.2011Gynecol Oncol 2011; 122:226-32
Joly Florence, Huober Jens, Dell'Anna Tiziana, Ferrandina Gabriella, Vergote Ignace, Reinthaller Alexander, Vaughan Michelle, Sugimoto Akira, Boman Karin, Donoghoe Mark, Fabbro Michel, Ray-Coquard Isabelle, Pujade-Lauraine Eric
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
von Minckwitz G, Zahm D, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, du Bois A, Blohmer J, Müller B, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Denkert C. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 2011; 29:2150-7.
25.04.2011Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy
25.04.2011J Clin Oncol 2011; 29:2150-7
von Minckwitz Gunter, Zahm Dirk-Michael, Khandan Fariba, Hoffmann Gerald, Gerber Bernd, Eidtmann Holger, Fend Falko, Dietel Manfred, Mehta Keyur, du Bois Andreas, Blohmer Jens Uwe, Müller Berit Maria, Loibl Sibylle, Budczies Jan, Hanusch Claus, Darb-Esfahani Silvia, Hilfrich Jörn, Weiss Erich, Huober Jens, Denkert Carsten
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
von Minckwitz G, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jackisch C, Hilfrich J, Mehta K, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching P, Eiermann W, Blohmer J, Costa S, Jüni P. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2010; 125:145-56.
03.11.2010Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
03.11.2010Breast Cancer Res Treat 2010; 125:145-56
von Minckwitz Gunter, Gerber Bernd, du Bois Andreas, Huober Jens, Hanusch Claus, Konecny Gottfried, Fett Werner, Stickeler Elmar, Harbeck Nadia, Müller Volkmar, Jackisch Christian, Hilfrich Jörn, Mehta Keyur, Untch Michael, Nüesch Eveline, Loibl Sibylle, Kaufmann Manfred, Kümmel Sherko, Fasching Peter A, Eiermann Wolfgang, Blohmer Jens-Uwe, Costa Serban Dan, Jüni Peter
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
Witzel I, Untch M, Roller M, Eulenburg C, Barinoff J, Hilfrich J, Just M, Latos K, Tesch H, Lantzsch T, Hauschild M, Henschen S, Hanusch C, Huober J, Mundhenke C, von Minckwitz G, Loibl S, Müller V. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. Breast Cancer Res Treat 2010; 123:437-45.
01.09.2010Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial
01.09.2010Breast Cancer Res Treat 2010; 123:437-45
Witzel Isabell, Untch Michael, Roller Marc, Eulenburg Christine Zu, Barinoff Jana, Hilfrich Jörn, Just Marianne, Latos Kunibert, Tesch Hans, Lantzsch Tilmann, Hauschild Maik, Henschen Stephan, Hanusch Claus, Huober Jens, Mundhenke Christoph, von Minckwitz Gunter, Loibl Sibylle, Müller Volkmar
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
du Bois A, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Kurzeder C, Weber B, Herrstedt J, Hardy-Bessard A, Müller H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162-9.
23.08.2010Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
23.08.2010J Clin Oncol 2010; 28:4162-9
du Bois Andreas, Jelic Svetislav, Pujade-Lauraine Eric, Burges Alexander, Pfisterer Jacobus, Gropp Martina, Staehle Anne, Wimberger Pauline, Jackisch Christian, Kurzeder Christian, Weber Béatrice, Herrstedt Jørn, Hardy-Bessard Anne-Claire, Müller Hans-Helge, Harter Philipp, Kristensen Gunnar, Joly Florence, Huober Jens, Avall-Lundqvist Elisabeth, Sehouli Jalid
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Huober J, Mehta K, Darb-Esfahani S, Högel B, Thomssen C, Hauschild M, Khandan F, Belau A, Zahm D, Weiss E, Tesch H, Denkert C, von Minckwitz G, Loibl S. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124:133-40.
10.08.2010Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
10.08.2010Breast Cancer Res Treat 2010; 124:133-40
Huober Jens, Mehta Keyur, Darb-Esfahani Silvia, Högel Bernhard, Thomssen Christoph, Hauschild Maik, Khandan Fariba, Belau Antje, Zahm Dirk Michael, Weiss Erich, Tesch Hans, Denkert Carsten, von Minckwitz Gunter, Loibl Sibylle
New Developments in Breast Cancer Therapy Presented at ASCO 2010
Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G. New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care (Basel) 2010; 5:266-271.
09.08.2010New Developments in Breast Cancer Therapy Presented at ASCO 2010
09.08.2010Breast Care (Basel) 2010; 5:266-271
Müllera Volkmar, Dubsky Peter, Fehm Tanja, Fitzal Florian, Huober Jens, Schmidt Marcus, Steger Günther
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol 2010; 22:80-5.
01.07.2010Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
01.07.2010Ann Oncol 2010; 22:80-5
Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Muller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober Jens, Spirig C, Lerch S, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)